```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1              Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02      LMEDLINE coverage updated
 NEWS  3  JUL 02      SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02      CHEMCATS accession numbers revised
 NEWS  5  JUL 02      CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16      CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18      CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26      USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30      USGENE now available on STN
 NEWS 10  AUG 06      CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06      FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13      CA/CAplus enhanced with additional kind codes for granted
                      patents
 NEWS 13  AUG 20      CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27      Full-text patent databases enhanced with predefined
                      patent family display formats from INPADOCDB
 NEWS 15  AUG 27      USPATOLD now available on STN
 NEWS 16  AUG 28      CAS REGISTRY enhanced with additional experimental
                      spectral property data
 NEWS 17  SEP 07      STN AnaVist, Version 2.0, now available with Derwent
                      World Patents Index
 NEWS 18  SEP 13      FORIS renamed to SOFIS
 NEWS 19  SEP 13      INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17      CA/CAplus enhanced with printed CA page images from
                      1967-1998
 NEWS 21  SEP 17      CAplus coverage extended to include traditional medicine
                      patents
 NEWS 22  SEP 24      EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02      CA/CAplus enhanced with pre-1907 records from Chemisches
                      Zentralblatt
 NEWS 24  OCT 19      BEILSTEIN updated with new compounds
 NEWS 25  NOV 15      Derwent Indian patent publication number format enhanced
 NEWS 26  NOV 19      WPIX enhanced with XML display format
 NEWS 27  NOV 30      ICSD reloaded with enhancements
 NEWS 28  DEC 04      LINPADOCDB now available on STN

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
```

```
  STN maintenance downtime to be extended

  The normal maintenance downtime for STN will be extended on December
  15.  STN will be unavailable beginning Saturday, December 15, at 17:00
  U.S. Eastern Standard Time until Sunday, December 16, at 01:00.

  The normal schedule for STN maintenance downtime (22:00 to 01:00) will
  resume on December 22.
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:27:31 ON 14 DEC 2007

=> file medline, uspatful, dgene, embase, wpids,
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.84       0.84

FILE 'MEDLINE' ENTERED AT 10:29:35 ON 14 DEC 2007

FILE 'USPATFULL' ENTERED AT 10:29:35 ON 14 DEC 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 10:29:35 ON 14 DEC 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 10:29:35 ON 14 DEC 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 10:29:35 ON 14 DEC 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

=> s (pharmaceutical composition)
L1      608534 (PHARMACEUTICAL COMPOSITION)

=> s l1 (Toll-like receptor 8)
MISSING OPERATOR 'L6 (TOLL-LIKE'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s (Toll-like receptor 8)
L2        1024 (TOLL-LIKE RECEPTOR 8)

=> s l2 and l1
L3         308 L2 AND L1

=> s (imidazoquinoline amine)
L4         165 (IMIDAZOQUINOLINE AMINE)

=> s l4 and l3
L5          40 L4 AND L3

=> s l5 and (1,2-bridged imidazoquinoline amine)
L6           7 L5 AND (1,2-BRIDGED IMIDAZOQUINOLINE AMINE)

=> d l6  ti abs ibib tot
```

L6 ANSWER 1 OF 7 USPATFULL on STN

TI Methods and products for enhancing immune responses using imidazoquinoline compounds

AB The invention involves administration of an imidazoquinoline agent in combination with another therapeutic agent. The combination of drugs may be administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs. The combinations can be used to enhance ADCC, stimulate immune responses and/or patient and treat certain disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2006:221633 USPATFULL
TITLE:	Methods and products for enhancing immune responses using imidazoquinoline compounds
INVENTOR(S):	Krieg, Arthur M., Wellesley, MA, UNITED STATES Schetter, Christian, Hilden, GERMANY, FEDERAL REPUBLIC OF Bratzler, Robert L., Concord, MA, UNITED STATES Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF Jurk, Marion, Dormagen, GERMANY, FEDERAL REPUBLIC OF Bauer, Stefan, Munich, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S):	University of Iowa Research Foundation, Iowa City, IA, UNITED STATES (U.S. corporation) Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation) Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006188913	A1	20060824
APPLICATION INFO.:	US 2006-368334	A1	20060303 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-272502, filed on 15 Oct 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-329208P	20011012 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US
NUMBER OF CLAIMS:	95
EXEMPLARY CLAIM:	1-87
NUMBER OF DRAWINGS:	19 Drawing Page(s)
LINE COUNT:	7069

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 7 USPATFULL on STN

TI Methods and compositions related to IRM compounds and toll-like receptor 8

AB Methods of eliciting a TLR8-mediated cellular response are disclosed. Such methods include administration of either a TLR8 agonist or a TLR8 antagonist to an IRM-responsive cell so that the IRM compound affects at least one TLR8-mediate cellular signaling pathway. In some cases, the method may provide prophylactic or therapeutic treatment for a condition treatable by modulating a TLR8-mediated cellular pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:209875 USPATFULL
TITLE:	Methods and compositions related to IRM compounds and toll-like receptor 8

INVENTOR(S): Gorden, Keith B., Maplewood, MN, UNITED STATES
Qiu, Xiaohong, Rosemount, MN, UNITED STATES
Vasilakos, John P., Woodbury, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004162309	A1	20040819	
APPLICATION INFO.:	US 2004-777310	A1	20040212	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-447179P	20030213	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1684
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 7 USPATFULL on STN
TI Immunostimulatory compositions and methods of stimulating an immune response
AB The present invention provides immunostimulatory compositions that include an immune response modifier portion paired with an antigenic portion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:120085 USPATFULL
TITLE: Immunostimulatory compositions and methods of stimulating an immune response
INVENTOR(S): Kedl, Ross M., Roseville, MN, UNITED STATES
Griesgraber, George W., Eagan, MN, UNITED STATES
Zarraga, Isidro Angelo E., Minneapolis, MN, UNITED STATES
PATENT ASSIGNEE(S): 3M Innovative Properties Company (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004091491	A1	20040513	
APPLICATION INFO.:	US 2003-640904	A1	20030814	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-403846P	20020815	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1442
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 7 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
TI Inducing immune response in subject against antigen, e.g. cancer antigen, by administering composition comprising imidazoquinoline agent that induces Toll-like receptor 8
-mediated signal transduction to subject, orally/parenterally
AN 2006-658094 [68] WPIDS

CR 2003-829705

AB US 20060188913 A1 UPAB: 20061023

NOVELTY - Inducing an immune response in a subject against an antigen, comprising administering a composition comprising an imidazoquinoline agent, which induces Toll-like receptor 8 (TLR8)-mediated signal transduction, to a subject, where the composition further comprises an antigen to induce an immune response, is new.

DETAILED DESCRIPTION - Inducing (M1) an immune response in a subject against an antigen, involves administering a composition comprising an imidazoquinoline agent, where the imidazoquinoline agent induces Toll-like receptor 8 (TLR8)-mediated signal transduction, to a subject by a route of administration chosen from mucosal, oral, intranasal, intratracheal, ocular, vaginal, rectal, buccal, and by inhalation, where the composition further comprises an antigen, in an effective amount to induce an immune response to the antigen.

INDEPENDENT CLAIMS are included for:

(1) enhancing an immune response to a cancer vaccine in a subject, involves administering a composition comprising an imidazoquinoline agent to the subject by a route of administration as in (M1), where the composition further comprises a cancer vaccine, where the imidazoquinoline agent enhances an immune response to the cancer vaccine;

(2) a pharmaceutical composition (PC) comprising an antigen and an imidazoquinoline agent, where the imidazoquinoline agent is an imidazoquinoline agent that induces TLR8-mediated signal transduction, or its pharmaceutically acceptable form, formulated for administration by a route chosen from mucosal, oral, intranasal, intratracheal, ocular, vaginal, rectal, buccal, and by inhalation;

(3) a kit comprising a sustained release vehicle comprising an imidazoquinoline agent and a container housing an antigen and instructions for timing of administration of the compounds;

(4) generating (M2) an immune response in a subject against an antigen, involves topically administering a TLR8 agonist immune response modified (IRM) compound to an administration site of the subject in an amount effective to potentiate an immune response to an antigen, and administering at the administration site a pharmaceutical composition comprising the antigen in an amount effective to generate an immune response to the antigen, or (b) topically administering an IRM compound to an administration site of the subject in an amount effective to potentiate an immune response to an antigen, and administering at the administration site a pharmaceutical composition comprising the antigen in an amount effective to generate an immune response to the antigen, where the IRM compound is a substituted imidazoquinoline amine, tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1, 2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, or a thiazolonaphthyridine amine;

(5) increasing an immune response raised by a subject in response to administering a vaccine at a vaccination site, involves topically administering an IRM compound or a TLR8 agonist IRM compound to the subject at the vaccination site in an amount effective to increase the immune response to the vaccine;

(6) pharmaceutical combination comprising a component that comprises an antigen and a topical formulation that comprises TLR8 agonist, or an IRM compound, or a pharmaceutically acceptable form; and

(7) a kit comprising a first container that contains a pharmaceutical composition that includes an antigen, and a second container that includes an IRM compound, or a pharmaceutically acceptable form.

ACTIVITY - Cytostatic; Antiallergic; Antibacterial; Virucide; Fungicide.

MECHANISM OF ACTION - Immune response inducer; TLR7/8 agonist; Vaccine; Synergist.

The CpCi oligodeoxynucleotides (ODNs) and R-848 were tested either together or individually for their ability to augment a cytolytic T lymphocyte (CTL) response against antigen (e.g. HbsAg) in vivo. CTL activity was measured at 4 weeks post prime. R-848 was able to augment the CTL response over antigen alone. The combination of R-848 and CpG ODN together resulted in at least an additive effect. No augmentation of CTL response over antigen alone was observed using control ODN either alone or with R-848.

USE - The method (M1) is useful for inducing an immune response in a subject against an antigen chosen from microbial antigen and cancer antigen or allergen. The antigen comprises an intact bacterium, an intact virus, or an intact fungus (claimed).

DESCRIPTION OF DRAWINGS - The figure is a graph representing hTLR9-mediated activation of NF-kappa B by CpG ODN 2006, but not by R-848.

ACCESSION NUMBER: 2006-658094 [68] WPIDS
CROSS REFERENCE: 2003-829705
DOC. NO. CPI: C2006-201379 [68]
DOC. NO. NON-CPI: N2006-527218 [68]
TITLE: Inducing immune response in subject against antigen, e.g. cancer antigen, by administering composition comprising imidazoquinoline agent that induces Toll-like receptor 8-mediated signal transduction to subject, orally/parenterally
DERWENT CLASS: B04; D16; S03; T01
INVENTOR: BAUER S; BRATZLER R L; JURK M; KRIEG A M; SCHETTER C; VOLLMER J
PATENT ASSIGNEE: (IOWA-C) UNIV IOWA RES FOUND; (COLE-N) COLEY PHARM GMBH; (COLE-N) COLEY PHARM GROUP INC
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20060188913	A1	20060824	(200668)*	EN	107	[20]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20060188913	A1 Provisional	US 2001-329208P	20011012
US 20060188913	A1 Cont of	US 2002-272502	20021015
US 20060188913	A1	US 2006-368334	20060303

PRIORITY APPLN. INFO: US 2006-368334 20060303
US 2001-329208P 20011012
US 2002-272502 20021015

L6 ANSWER 5 OF 7 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
TI Activating neutrophils by contacting neutrophils with a toll-like receptor 8-selective agonist and/or with a neutrophil-activating immune response modified compound activate the neutrophils
AN 2005-345051 [35] WPIDS
AB US 20050096259 A1 UPAB: 20051222

NOVELTY - Activating neutrophils comprises contacting neutrophils with a toll-like receptor (TLR8)-selective agonist and/or with a neutrophil-activating immune response modified (IRM) compound in an amount to activate the neutrophils.

DETAILED DESCRIPTION - Activating neutrophils comprises contacting

neutrophils with a TLR8-selective agonist and/or with a neutrophil-activating IRM compound in an amount to activate the neutrophils, where the neutrophil-activating compound comprises a substituted imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1, 2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, or a thiazolonaphthyridine amine.

INDEPENDENT CLAIMS are also included for the following:

(1) a method of treating a condition in a subject; and

(2) a pharmaceutical composition comprising a TLR8-selective agonist and/or a neutrophil-activating IRM compound in an amount to activate neutrophils.

ACTIVITY - Antibacterial; Cytostatic. No biological data given.

MECHANISM OF ACTION - Gene Therapy.

USE - The method is useful for activating neutrophils. It is useful for treating a condition treatable by activating neutrophils. The condition include bacterial infection and neoplastic disease including intraepithelial neoplasia, cervical dysplasia, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, hairy cell leukemia, Karposi's sarcoma, melanoma, renal cell carcinoma, myelogeous leukemia, multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, cutaneous T-cell lymphoma, B-cell lymphoma, colorectal cancer, breast cancer, or lung cancer.

ACCESSION NUMBER: 2005-345051 [35] WPIDS
DOC. NO. CPI: C2005-106710 [35]
TITLE: Activating neutrophils by contacting neutrophils with a toll-like receptor 8 -selective agonist and/or with a neutrophil-activating immune response modified compound activate the neutrophils
DERWENT CLASS: B05
INVENTOR: TOMAI M A; VASILAKOS J P; WIGHTMAN P D
PATENT ASSIGNEE: (MINN-C) 3M INNOVATIVE PROPERTIES CO
COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20050096259	A1	20050505	(200535)*	EN	10	[1]
WO 2005041891	A2	20050512	(200535)	EN		
EP 1680080	A2	20060719	(200647)	EN		
AU 2004285575	A1	20050512	(200680)	EN		
JP 2007509987	W	20070419	(200729)	JA	19	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20050096259	A1 Provisional	US 2003-516116P	20031031
US 20050096259	A1 Provisional	US 2003-517805P	20031106
US 20050096259	A1	US 2004-978850	20041101
AU 2004285575	A1	AU 2004-285575	20041101
EP 1680080	A2	EP 2004-810205	20041101
WO 2005041891	A2	WO 2004-US36351	20041101
EP 1680080	A2	WO 2004-US36351	20041101
JP 2007509987	W	WO 2004-US36351	20041101
JP 2007509987	W	JP 2006-538418	20041101

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1680080	A2	Based on	WO 2005041891	A
AU 2004285575	A1	Based on	WO 2005041891	A
JP 2007509987	W	Based on	WO 2005041891	A

PRIORITY APPLN. INFO: US 2004-978850 20041101
US 2003-516116P 20031031
US 2003-517805P 20031106

L6 ANSWER 6 OF 7 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
TI Generating an immune response in a subject against an antigen by topically administering a Toll-like receptor 8 (TLR8) agonist immune response modifier (IRM) compound and a pharmaceutical composition comprising the antigen
AN 2005-202050 [21] WPIDS
AB US 20050048072 A1 UPAB: 20050708
NOVELTY - Generating an immune response in a subject against an antigen comprises topically administering a Toll-like receptor 8 (TLR8) agonist immune response modifier (IRM) compound to an administration site of the subject to potentiate an immune response to an antigen and administering at the administration site a pharmaceutical composition comprising the antigen to generate an immune response to the antigen.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method of increasing an immune response raised by a subject in response to administering a vaccine at a vaccination site;

(2) a pharmaceutical combination comprising a component that comprises an antigen and a topical formulation that comprises TLR8 agonist, or its pharmaceutically acceptable form; and

(3) a kit comprising a first container that contains a pharmaceutical composition that includes an antigen and a second container that includes an IRM compound, or its pharmaceutically acceptable form.

ACTIVITY - Antibacterial; Virucide; Cytostatic; Fungicide; Immunostimulant. No biological data given.

MECHANISM OF ACTION - Vaccine.

USE - The method is useful in generating an immune response in a subject against bacterial, viral, fungal or tumor-derived antigen (claimed).

ACCESSION NUMBER: 2005-202050 [21] WPIDS
DOC. NO. CPI: C2005-064424 [21]
TITLE: Generating an immune response in a subject against an antigen by topically administering a Toll-like receptor 8 (TLR8) agonist immune response modifier (IRM) compound and a pharmaceutical composition comprising the antigen
DERWENT CLASS: B04; B05; D16; P34
INVENTOR: KEDL R; KEDL R M; TOMAI M A; VASILAKOS J P; WOLTER J; WOLTER J T; TOMAI M; VASILAKOS J
PATENT ASSIGNEE: (MINN-C) 3M INNOVATIVE PROPERTIES CO; (KEDL-I) KEDL R M; (WOLT-I) WOLTER J T
COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20050048072	A1	20050303	(200521)*	EN	16[4]	
WO 2005018574	A2	20050303	(200521)	EN		
WO 2005020912	A2	20050310	(200521)	EN		
EP 1658035	A2	20060524	(200635)	EN		

EP 1660122	A2	20060531	(200636)	EN	
US 20060195067	A1	20060831	(200657)#	EN	
AU 2004266162	A1	20050303	(200670)	EN	
AU 2004268616	A1	20050310	(200670)	EN	
JP 2007503268	W	20070222	(200717)	JA	26
JP 2007504145	W	20070301	(200718)	JA	27

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20050048072	A1 Provisional	US 2003-497628P	20030825
US 20050048072	A1 Provisional	US 2003-524213P	20031121
US 20050048072	A1	US 2004-925473	20040825
US 20060195067	A1 Provisional	US 2003-497628P	20030825
AU 2004266162	A1	AU 2004-266162	20040825
AU 2004268616	A1	AU 2004-268616	20040825
EP 1658035	A2	EP 2004-782185	20040825
EP 1660122	A2	EP 2004-801917	20040825
WO 2005018574	A2	WO 2004-US27712	20040825
WO 2005020912	A2	WO 2004-US27633	20040825
EP 1658035	A2	WO 2004-US27633	20040825
EP 1660122	A2	WO 2004-US27712	20040825
JP 2007503268	W	WO 2004-US27633	20040825
US 20060195067	A1	WO 2004-US27633	20040825
JP 2007503268	W	JP 2006-524827	20040825
US 20060195067	A1	US 2006-595073	20060130
JP 2007504145	W	WO 2004-US27712	20040825
JP 2007504145	W	JP 2006-524843	20040825

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1660122	A2	Based on	WO 2005018574	A
AU 2004266162	A1	Based on	WO 2005018574	A
EP 1658035	A2	Based on	WO 2005020912	A
AU 2004268616	A1	Based on	WO 2005020912	A
JP 2007503268	W	Based on	WO 2005020912	A
JP 2007504145	W	Based on	WO 2005018574	A

PRIORITY APPLN. INFO:	US 2004-925473	20040825
	US 2003-497628P	20030825
	US 2003-524213P	20031121
	US 2006-595073	20060130

L6 ANSWER 7 OF 7 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN

TI Eliciting Toll-like receptor 8 mediated cellular response in cell that expresses Toll-like receptor 8 used for treating e.g. allergy or atopic dermatitis, comprises administering Toll-like receptor 8 agonist or antagonist to cell

AN 2004-624809 [60] WPIDS

AB US 20040162309 A1 UPAB: 20060122

NOVELTY - Eliciting a Toll-like receptor 8 (TLR8)-mediated cellular response in a cell that expresses TLR8 comprises administering a TLR8 agonist or antagonist to the cell in an amount that affects at least one TLR8-mediated cellular signalling pathway. The TLR8 agonist or antagonist is e.g. a substituted imidazoquinoline amine or a tetrahydroimidazoquinoline amine.

DETAILED DESCRIPTION - Eliciting a Toll-like receptor 8 (TLR8)-mediated cellular response in a cell that expresses TLR8 comprises administering a TLR8 agonist or antagonist

to the cell in an amount that affects at least one TLR8-mediated cellular signalling pathway. The TLR8 agonist or antagonist is a substituted imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline, amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine, or a 1H-imidazo dimer fused to pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine or tetrahydronaphthyridine amine.

INDEPENDENT CLAIMS are also included for:

(1) identifying a TLR8 agonist which comprises exposing a TLR8 positive cell culture to a test compound and measuring a TLR8 mediated cellular response, exposing a TLR8 negative cell culture to a test compound and measuring a TLR8 mediated cellular response, and identifying the test compound as a TLR8 agonist if the cellular response in the TLR8-positive cell culture is greater than the cellular response of the TLR8 negative cell culture;

(2) identifying a TLR8 antagonist which comprises exposing a first immune responsive modifier (IRM) responsive cell culture to a TLR8 agonist and measuring a TLR8-mediated cellular response, exposing a second IRM responsive cell culture to a TLR8 agonist and a test compound and measuring a TLR8-mediated cellular response, and identifying the test compound as a TLR8 antagonist if the cellular response in the first cell culture is greater than the cellular response of the second cell culture;

(3) a compound identified as a TLR8 agonist or antagonist as above, and

(4) a pharmaceutical composition which comprises a TLR8 agonist or antagonist in combination with a carrier.

ACTIVITY - Cytostatic; Antiallergic; Antiinflammatory; Dermatological; Virucide; Antibacterial; Antiparasitic; Protozoacide; Cerebroprotective; Immunosuppressive; Antiasthmatic; Neuroprotective; Endocrine-Gen.; Vulnerary.

No biological data is given.

MECHANISM OF ACTION - TLR8 Agonist; TLR8 antagonist.

USE - Used for treating neoplastic disease or a TH2-mediated disease, particularly allergic rhinitis or atopic dermatitis, or a viral disease, a bacterial disease, a parasitic disease, a protozoal disease, or a prion-mediated disease. A dominant-negative variant of TLR8 is useful for identifying a compound that activates a TLR8-mediated cellular signaling pathway. An IRM compound is useful as a positive control in an assay detecting activation of TLR8, where the IRM compound comprises the amine derivatives defined above (all claimed). The IRMs are useful as vaccine adjuvants. Other TH2-mediated diseases that can be treated include autoimmune diseases such as eczema, eosinophilia, asthma, allergy, systemic lupus erythematosus, essential thrombocythemia, multiple sclerosis, Ommen's syndrome, discoid lupus, alopecia areata, inhibition of keloid formation and other types of scarring, and enhancing wound healing including chronic wounds.

ACCESSION NUMBER: 2004-624809 [60] WPIDS
DOC. NO. CPI: C2004-224627 [60]
TITLE: Eliciting Toll-like receptor 8 mediated cellular response in cell that expresses Toll-like receptor 8 used for treating e.g. allergy or atopic dermatitis, comprises administering Toll-like receptor 8 agonist or antagonist to cell
DERWENT CLASS: B02
INVENTOR: GORDEN K B; QIU X; VASILAKOS J P
PATENT ASSIGNEE: (MINN-C) 3M INNOVATIVE PROPERTIES CO

COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20040162309	A1	20040819	(200460)*	EN	25	[11]
WO 2004071459	A2	20040826	(200460)	EN		
EP 1592302	A2	20051109	(200573)	EN		
JP 2006517974	W	20060803	(200651)	JA	40	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20040162309	A1 Provisional	US 2003-447179P	20030213
US 20040162309	A1	US 2004-777310	20040212
EP 1592302	A2	EP 2004-710701	20040212
WO 2004071459	A2	WO 2004-US4353	20040212
EP 1592302	A2	WO 2004-US4353	20040212
JP 2006517974	W	WO 2004-US4353	20040212
JP 2006517974	W	JP 2006-503575	20040212

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1592302	A2	Based on	WO 2004071459	A
JP 2006517974	W	Based on	WO 2004071459	A

PRIORITY APPLN. INFO: US 2004-777310 20040212
US 2003-447179P 20030213

=> d his

(FILE 'HOME' ENTERED AT 10:27:31 ON 14 DEC 2007)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 10:29:35 ON 14 DEC 2007

L1 608534 S (PHARMACEUTICAL COMPOSITION)
L2 1024 S (TOLL-LIKE RECEPTOR 8)
L3 308 S L2 AND L1
L4 165 S (IMIDAZOQUINOLINE AMINE)
L5 40 S L4 AND L3
L6 7 S L5 AND (1,2-BRIDGED IMIDAZOQUINOLINE AMINE)

=> s l1 and l2
L7 308 L1 AND L2

=> s l7 and (2-amino pyridine)
L8 0 L7 AND (2-AMINO PYRIDINE)

=> s (2-amino pyridine)
L9 589 (2-AMINO PYRIDINE)

=> s l9 and l7
L10 0 L9 AND L7

=> s l9 and l2
L11 0 L9 AND L2

=> s l9 and (5-membered nitrogen containing heterocyclic ring)
L12 0 L9 AND (5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING)

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  JUL 02   LMEDLINE coverage updated
 NEWS  3  JUL 02   SCISEARCH enhanced with complete author names
 NEWS  4  JUL 02   CHEMCATS accession numbers revised
 NEWS  5  JUL 02   CA/CAplus enhanced with utility model patents from China
 NEWS  6  JUL 16   CAplus enhanced with French and German abstracts
 NEWS  7  JUL 18   CA/CAplus patent coverage enhanced
 NEWS  8  JUL 26   USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS  9  JUL 30   USGENE now available on STN
 NEWS 10  AUG 06   CAS REGISTRY enhanced with new experimental property tags
 NEWS 11  AUG 06   FSTA enhanced with new thesaurus edition
 NEWS 12  AUG 13   CA/CAplus enhanced with additional kind codes for granted
                   patents
 NEWS 13  AUG 20   CA/CAplus enhanced with CAS indexing in pre-1907 records
 NEWS 14  AUG 27   Full-text patent databases enhanced with predefined
                   patent family display formats from INPADOCDB
 NEWS 15  AUG 27   USPATOLD now available on STN
 NEWS 16  AUG 28   CAS REGISTRY enhanced with additional experimental
                   spectral property data
 NEWS 17  SEP 07   STN AnaVist, Version 2.0, now available with Derwent
                   World Patents Index
 NEWS 18  SEP 13   FORIS renamed to SOFIS
 NEWS 19  SEP 13   INPADOCDB enhanced with monthly SDI frequency
 NEWS 20  SEP 17   CA/CAplus enhanced with printed CA page images from
                   1967-1998
 NEWS 21  SEP 17   CAplus coverage extended to include traditional medicine
                   patents
 NEWS 22  SEP 24   EMBASE, EMBAL, and LEMBASE reloaded with enhancements
 NEWS 23  OCT 02   CA/CAplus enhanced with pre-1907 records from Chemisches
                   Zentralblatt
 NEWS 24  OCT 19   BEILSTEIN updated with new compounds
 NEWS 25  NOV 15   Derwent Indian patent publication number format enhanced
 NEWS 26  NOV 19   WPIX enhanced with XML display format
 NEWS 27  NOV 30   ICSD reloaded with enhancements
 NEWS 28  DEC 04   LINPADOCDB now available on STN

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
```

STN maintenance downtime to be extended

The normal maintenance downtime for STN will be extended on December 15. STN will be unavailable beginning Saturday, December 15, at 17:00 U.S. Eastern Standard Time until Sunday, December 16, at 01:00.

The normal schedule for STN maintenance downtime (22:00 to 01:00) will resume on December 22.

* *

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:49:25 ON 14 DEC 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 11:51:06 ON 14 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2007 HIGHEST RN 957969-84-5
DICTIONARY FILE UPDATES: 13 DEC 2007 HIGHEST RN 957969-84-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s imidazoquinoline amine/cn
L1 0 IMIDAZOQUINOLINE AMINE/CN

=> s tetrahydroimidazoquinoline amine/cn
L2 0 TETRAHYDROIMIDAZOQUINOLINE AMINE/CN

=> s imidazopyridine amine/cn
L3 0 IMIDAZOPYRIDINE AMINE/CN

=> s 1,2-bridged imidazoquinoline amine
1319930 1,2
6 BRIDGED
0 IMIDAZOQUINOLINE
1827670 AMINE

```
L4            0 1,2-BRIDGED IMIDAZOQUINOLINE AMINE
                  (1,2(W)BRIDGED(W)IMIDAZOQUINOLINE(W)AMINE)

=> s 1,2-bridged imidazoquinoline amine/cn
L5            0 1,2-BRIDGED IMIDAZOQUINOLINE AMINE/CN

=> s 6,7-fused cycloalkylimidazopyridine amine/cn
L6            0 6,7-FUSED CYCLOALKYLIMIDAZOPYRIDINE AMINE/CN

=> s thiazoloquinoline amine/cn
L7            0 THIAZOLOQUINOLINE AMINE/CN

=> s oxazoloquinoline amine/cn
L8            0 OXAZOLOQUINOLINE AMINE/CN

=> s l4 and (2-aminopyridine)
      24665884 2
          1183 AMINOPYRIDINE
           288 2-AMINOPYRIDINE
                  (2(W)AMINOPYRIDINE)
L9            0 L4 AND (2-AMINOPYRIDINE)
```

Refine Search

Search Results -

Terms	Documents
L3 and L1	5

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L4

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Friday, December 14, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB; PLUR=YES; OP=OR			
L4	L3 and l1	5	L4
L3	(TLR-8 agonist)	42829	L3
L2	L1 and (TLR-8)	0	L2
L1	gorden.in.	25	L1

END OF SEARCH HISTORY

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 20050245564 A1

L4: Entry 1 of 5 File: PGPB Nov 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050245564
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050245564 A1

TITLE: Methods and compositions related to IRM compounds and toll-like receptor pathways

PUBLICATION-DATE: November 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Gorden, Keith B.	Maplewood	MN	US
Qiu, Xiaohong	Rosemount	MN	US
Tomai, Mark A.	Woodbury	MN	US
Vasilakos, John P.	Woodbury	MN	US

US-CL-CURRENT: 514/292

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 2. Document ID: US 20040171086 A1

L4: Entry 2 of 5 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040171086
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040171086 A1

TITLE: Selective modulation of TLR-mediated biological activity

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fink, Jason R.	Eagan	MN	US
Gorden, Keith B.	Maplewood	MN	US
Gorski, Kevin S.	White Bear Lake	MN	US
Gupta, Shalley K.	Woodbury	MN	US

Qiu, Xiaohong	Rosemount	MN	US
Vasilakos, John P.	Woodbury	MN	US

US-CL-CURRENT: 435/7.2; 514/1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 3. Document ID: US 20040162309 A1

L4: Entry 3 of 5 File: PGPB Aug 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040162309
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040162309 A1

TITLE: Methods and compositions related to IRM compounds and toll-like receptor 8

PUBLICATION-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Gorden, Keith B.	Maplewood	MN	US
Qiu, Xiaohong	Rosemount	MN	US
Vasilakos, John P.	Woodbury	MN	US

US-CL-CURRENT: 514/292

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 20040014779 A1

L4: Entry 4 of 5 File: PGPB Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014779
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040014779 A1

TITLE: Methods and compositions related to IRM compounds and toll-like recptor pathways

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Gorden, Keith B.	Maplewood	MN	US
Qiu, Xiaohong	Rosemount	MN	US
Tomai, Mark A.	Woodbury	MN	US
Vasilakos, John P.	St. Paul	MN	US

US-CL-CURRENT: 514/291; 514/292

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 20020039760 A1

L4: Entry 5 of 5 File: PGPB Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039760
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039760 A1

TITLE: Polynucleotides encoding novel secreted proteins

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Wong, Gorden G.	Brookline	MA	US
Clark, Hilary F.	San Francisco	CA	US
Fechtel, Kim	Arlington	MA	US
Agostino, Michael J.	Andover	MA	US
Howes, Steven H.	Cambridge	MA	US
Resnick, Richard J.	Somerville	MA	US
Gulukota, Kamalakar	Lawrenceville	NJ	US
Graham, James R.	Arlington	MA	US

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L3 and L1	5

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#